Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Virology Journal|September 18, 2012
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptidesAkimasa Fukui, Satoko Matsueda, Kouichiro Kawano, et al.
Biomaterials|February 25, 2011
Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen deliveryZhiping Zhang, Songsak Tongchusak, Yo Mizukami, et al.
European Journal of Immunology|March 21, 2003
Disparate peptide-dependent thymic selection outcomes in beta2M-deficient mice versus TAP-1-deficient mice: implications for repertoire formationTetsuro Sasada, Yuting Yang, Char-Chang Lai, et al.
International Journal of Oncology|February 7, 2012
Personalized peptide vaccination in patients with refractory non-small cell lung cancerKoichi Yoshiyama, Yasuhiro Terazaki, Satoko Matsueda, et al.
European Journal of Radiology|August 14, 2012
Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapyYoshiaki Zaizen, Koichi Azuma, Seiji Kurata, et al.
Respiratory Investigation|June 26, 2025
Exploration of plasma factor profiles involved in tumor growth factors in non-small cell carcinoma patients with interstitial pneumoniaGoushi Matama, Koichi Azuma, Akimasa Sekine, et al.
Cancer Science|February 12, 2017
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancerTakahisa Shirahama, Daisuke Muroya, Satoko Matsueda, et al.
Frontiers in Pharmacology|November 29, 2023
Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinomaYosuke Shibata, Takeshi Kishida, Taku Kouro, et al.
Cancer Chemotherapy and Pharmacology|January 6, 2009
Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiationKoichi Azuma, Tetsuro Sasada, Akihiko Kawahara, et al.
Cancer Immunology, Immunotherapy : CII|February 10, 2015
Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppressionMasanori Noguchi, Gaku Arai, Kazumasa Matsumoto, et al.
Pageof 14